ClinicalTrials.gg
CompletedNCT04324814Updated Feb 21, 2023

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of SHR-1701 in Advanced Solid Tumor, sponsored by Atridia Pty Ltd.. Completed at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.

Read the detailed description

This is a two-part, open-label, multicenter, non-randomized, dose escalation, Phase 1 study of repeated doses of SHR-1701 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Atridia Pty Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed (histologically or cytologically) with solid tumors
  • Performance Status of 0 or 1 at both the screening and baseline visits
  • ≥12 weeks
  • Adequate laboratory parameters
  • Willing and able to comply with clinic visits and study-related procedures
  • Provide signed

Exclusion criteria

Exclusion Criteria:

  • Known history of to the study drug
  • Prior active within the previous 2 years
  • Any or concurrent cancer therapy
  • History of immunodeficiency including seropositivity
  • Systemic antibiotics treatment for ≥ 7 days before the first dose
  • A known history of allogeneic organ transplantation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Dose level 1

    Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle

    Drug: SHR-1701

  • Experimental
    Dose level 2

    Subjects will receive a single dose of SHR-1701 at Dose level 2 on Day 1 of each cycle

    Drug: SHR-1701

  • Experimental
    Dose level 3

    Subjects will receive a single dose of SHR-1701 at Dose level 3 on Day 1 of each cycle

    Drug: SHR-1701

  • Experimental
    Dose level 4

    Subjects will receive a single dose of SHR-1701 at Dose level 2 1 on Day 1 and Day 15 of each cycle

    Drug: SHR-1701

  • Experimental
    Dose level 5

    Subjects will receive a single dose of SHR-1701 at Dose level 3 on Day 1 and Day 15 of each cycle

    Drug: SHR-1701

  • Experimental
    Dose expansion 1

    Subjects will receive a single dose of SHR-1701 on a selected dose level Day 1 of each cycle

    Drug: SHR-1701

  • Experimental
    Dose expansion 2

    Subjects will receive a single dose of SHR-1701 on a selected dose level on Day 1 of each cycle

    Drug: SHR-1701

Interventions

  • Anti-PD-L1/TGFβ fusion protein

06

What researchers measure

Primary outcomes

  1. Adverse events

    Number of subjects with adverse events (AEs)

    Time frame: Screening up to study completion, an average of 1 year

  2. Laboratory results

    Number of subjects with laboratory tests findings of potential clinical importance

    Time frame: Screening up to study completion, an average of 1 year

  3. Vital signs

    Incidence of vital sign abnormalities

    Time frame: Screening up to study completion, an average of 1 year

  4. Electrocardiogram

    Number of subjects with clinically significant abnormal ECG QT Interval

    Time frame: Screening up to study completion, an average of 1 year

Secondary outcomes

  1. Pharmacokinetic - Cmax

    Maximum observed plasma concentration (Cmax) of SHR-1701

    Time frame: Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15

  2. Pharmacokinetic - AUC∞

    Area under the concentration-time curve from time 0 to infinity of SHR-1701

    Time frame: Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15

  3. Pharmacokinetic - Tmax

    Time to Cmax of SHR-1701

    Time frame: Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15

  4. Pharmacokinetic - CL/F

    Apparent clearance of SHR-1701

    Time frame: Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15

  5. Pharmacokinetic - Vz/F

    Apparent volume of distribution during terminal phase of SHR-1701

    Time frame: Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15

  6. Pharmacokinetic - t1/2

    Terminal elimination half-life

    Time frame: Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15

  7. Pharmacodynamics- ADA

    Anti-drug antibody of PD-L1

    Time frame: Pre-dose on Day1 of cycle 2,3,4,5,7,9,13,17

07

Study locations

4 sites
  • Icon Cancer Care Centre
    South Brisbane, New South Wales 4101, Australia
  • Scientia Clinical research
    Sydney, New South Wales, Australia
  • Sydney South West Private
    Sydney, New South Wales, Australia
  • Linear Clinical Research
    Perth, Western Australia, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Feb 2023, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2019
First posted
Mar 27, 2020
StartActual
Mar 31, 2020
Primary completionActual
Feb 1, 2023
CompletionActual
Feb 1, 2023
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04324814
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Mar 27, 2020
Start date
Mar 31, 2020
Primary completion
Feb 1, 2023
Completion
Feb 1, 2023
Last update
Feb 21, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1701

Start the discussion